Skip to content
Mulpleta, Mulpleo (previously lusutrombopag shionogi)(lusutrombopag)
Mulpleo, Mulpleta (lusutrombopag) is a small molecule pharmaceutical. Lusutrombopag was first approved as Mulpleta on 2018-07-31. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. The pharmaceutical is active against thrombopoietin receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
Trade Name
FDA
EMA
Mulpleta
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lusutrombopag
Tradename
Company
Number
Date
Products
MULPLETAShionogiN-210923 RX2018-07-31
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
mulpletaNew Drug Application2020-10-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
thrombocytopeniaHP_0001873D013921D69.6
Agency Specific
FDA
EMA
Expiration
Code
LUSUTROMBOPAG, MULPLETA, SHIONOGI INC
2023-07-31NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Lusutrombopag, Mulpleta, Shionogi Inc
94274022031-09-29DP
85306682030-01-21DS, DP
88897222028-07-29DS, DP
76017462024-09-05DS, DPU-2344
ATC Codes
B: Blood and blood forming organ drugs
— B02: Antihemorrhagics
— B02B: Vitamin k and other hemostatics
— B02BX: Other systemic hemostatics in atc
— B02BX07: Lusutrombopag
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThrombocytopeniaD013921HP_0001873D69.6——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.3—2———2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLUSUTROMBOPAG
INNlusutrombopag
Description
Lusutrombopag is a member of cinnamic acids.
Classification
Small molecule
Drug classthrombopoetin agonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC
Identifiers
PDB—
CAS-ID1110766-97-6
RxCUI—
ChEMBL IDCHEMBL2107831
ChEBI ID—
PubChem CID49843517
DrugBankDB13125
UNII ID6LL5JFU42F (ChemIDplus, GSRS)
Target
Agency Approved
MPL
MPL
Organism
Homo sapiens
Gene name
MPL
Gene synonyms
TPOR
NCBI Gene ID
4352
Protein name
thrombopoietin receptor
Protein synonyms
CD110, Myeloproliferative leukemia protein, myeloproliferative leukemia virus oncogene, Proto-oncogene c-Mpl, TPO-R
Uniprot ID
Q5JUZ0
Mouse ortholog
Mpl (17480)
thrombopoietin receptor (Q08351)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 163 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
286 adverse events reported
View more details